Enovis Corporation (NYSE: ENOV): Corporate Profile & Financials

Source: Form 10-K For the fiscal year ended December 31, 2025

Quick Facts / Company Snapshot

Company Overview

Enovis Corporation is an innovation-driven medical technology company focused on developing clinically differentiated solutions that generate measurably better patient outcomes and transform healthcare workflows. The Company designs, manufactures, and distributes high-quality medical devices and services used for reconstructive surgery, rehabilitation, pain management, and physical therapy. Enovis products address the complete continuum of patient care, spanning injury prevention, pre-operative planning, joint replacement, post-surgical recovery, and rehabilitation from degenerative conditions or traumatic injuries.

The enterprise conducts its global operations through two primary reportable segments: Prevention & Recovery and Reconstructive. At the core of the Company’s operational philosophy is the Enovis Growth Excellence (EGX) business system. EGX represents a set of tools, repeatable processes, and an organizational culture designed to drive continuous improvement, optimize quality, delivery, and cost structures, and accelerate organic and inorganic business growth.

Business Segments

Enovis operates and manages its organizational structure across two specialized medical technology segments:

• Prevention & Recovery (P&R): Focuses on non-surgical and post-operative orthopedic care solutions. P&R provides rigid and soft bracing products, vascular therapy systems, compression garments, hot and cold therapy devices, bone growth stimulators, and electrical stimulation devices used for clinical pain management and physical therapy. This segment reaches healthcare providers, clinics, hospitals, direct-to-patient channels, and retail channels.
• Reconstructive (Recon): Focuses on surgical implant solutions for elective and non-elective joint replacement, limb reconstruction, and extremities. The segment provides specialized implant systems, surgical instrumentation, enabling digital technologies, and computer-assisted planning tools for shoulder, hip, knee, elbow, foot, ankle, and finger procedures.

History and Evolution

Enovis Corporation was originally organized as a Delaware corporation in 1998 under the name Colfax Corporation, operating for many years as a diversified manufacturing and technology firm. On April 4, 2022, the enterprise completed a major strategic transformation by separating its industrial fabrication technology business (ESAB Corporation) into an independent publicly traded entity. Following the separation, the remaining company rebranded as Enovis Corporation and began trading under the NYSE ticker symbol ENOV.

In recent years, Enovis has pursued an aggressive growth strategy combining organic product development with targeted strategic acquisitions:

• 2023 Strategic Expansion: Acquired Novastep on June 28, 2023, enhancing its foot and ankle portfolio with minimally invasive surgery (MIS) solutions; acquired external fixation assets from SEAL on July 20, 2023; and acquired 100% of Precision AI on October 5, 2023, integrating advanced surgical planning software.
• 2024 Lima Acquisition: On January 3, 2024, Enovis completed the acquisition of LimaCorporate S.p.A. (Lima), a global orthopedic company specializing in digital innovation and customized hardware, significantly extending the Recon segment’s global footprint and technology portfolio.
• 2025 Portfolio Optimization: Completed four complementary acquisitions within the Recon segment and three within the P&R segment. On October 7, 2025 (effective October 4, 2025), Enovis completed the divestiture of its Dr Comfort Footcare Solutions U.S. operations.

Products and Services

Enovis manufactures a broad portfolio of medical devices and technology platforms tailored to orthopedic specialists, surgeons, physical therapists, podiatrists, and healthcare networks:

• Orthopedic Bracing & Supports: Rigid bracing, soft goods, and support systems designed for ligament protection, joint stabilization, and injury prevention.
• Recovery Sciences & Vascular Therapies: Bone growth stimulation devices, vascular therapy systems, compression garments, electrical neuromuscular stimulation systems, and therapeutic hot/cold devices.
• Surgical Joint Implants: Primary and revision joint replacement systems for shoulders, knees, hips, and extremity reconstruction.
• Extremity & Limb Reconstruction: Minimally invasive bunion surgery technology, plating systems, and external fixation frames for complex foot and ankle procedures.
• Enabling Technologies & Digital Planning: Software platforms and computer-assisted technologies that support pre-operative surgical planning, intra-operative execution, and post-operative monitoring.

Brand Portfolio

The Company markets its solutions globally under well-recognized medical brands and registered trademarks, including:

• DonJoy: Premier rigid bracing and orthopedic support systems.
• Aircast: Specialized orthopedic bracing, ankle stirrups, and vascular compression devices.
• Chattanooga: Rehabilitation equipment and electrical stimulation devices for physical therapy and pain management.
• LimaCorporate: Advanced surgical implant solutions, 3D-printed titanium implants, and custom hardware.
• Novastep: Specialized minimally invasive surgery devices for foot and ankle procedures.

Geographical Presence

Enovis maintains commercial operations and distribution channels across North America, Europe, Africa, Asia, and Australia. Manufacturing, distribution, and administrative operations are conducted across multiple facility footprints:

• Prevention & Recovery Facilities: Five operational facilities in the United States covering 241,000 square feet of leased space; eleven facilities outside the United States totaling 925,000 square feet of leased space across nine countries.
• Reconstructive Facilities: Four facilities in the United States covering 213,000 square feet of leased space; four facilities outside the United States comprising 268,000 square feet of owned space and 18,000 square feet of leased space across three European countries.

Board of Directors and Leadership Team

The Enovis executive leadership team and Board of Directors oversee global operations and strategic initiatives:

• Damien McDonald: Chief Executive Officer and Director
• Phillip B. Berry: Senior Vice President and Chief Financial Officer
• Oliver Engert: Chief Administrative Officer
• Bradley J. Tandy: Senior Vice President and Chief Legal Officer
• Patricia Lang: Senior Vice President and Chief Human Resources Officer
• Terry D. Ross: Group President, Prevention & Recovery
• Louis Vogt: Group President, Reconstructive
• Board of Directors: Sharon L. Wienbar (Chair), Damien McDonald, Brady R. Shirley, Liam J. Kelly, Philip Okala, A. Clayton Perfall, Rajiv Vinnakota, Dr. Christine Ortiz, Angela S. Lalor, Barbara Bodem.

Creating Better Together

Enovis Corporate Purpose

Future Strategy

Enovis executes a growth strategy focused on expanding its market presence in global orthopedics and clinical recovery:

• Continuous EGX Deployment: Deepening the application of EGX business management principles across all acquired entities to enhance operational efficiency, product quality, and margin performance.
• Surgeon Collaboration & Innovation: Partnering with orthopedic surgeons to design, test, and bring to market next-generation reconstructive implants and enabling technologies.
• Expansion of High-Growth Surgical Portfolios: Accelerating commercial growth in shoulder, extremity, and foot/ankle markets through advanced digital pre-operative planning and surgical tools.
• Global Integration & Optimization: Streamlining supply chain networks, consolidating software infrastructure, and establishing global shared service operations following major international acquisitions.

Key Strengths

• Comprehensive Care Continuum: Capability to treat patients across the entire healthcare spectrum, from non-surgical injury prevention to total joint reconstruction and post-operative therapy.
• Proprietary EGX Business System: A structured organizational platform driving repeatable improvements in operating capabilities and operational integration.
• Recognized Global Brands: Industry-leading medical device brands backed by extensive clinical evidence and surgeon adoption.
• Robust IP Portfolio: Extensive patent, trademark, and proprietary process protection across key orthopedics markets worldwide.
• Diverse Distribution Channels: Multi-channel sales force leveraging direct sales representatives, independent sales agencies, and third-party global distributors.

Key Challenges and Risks

• Acquisition Integration & Realization of Synergies: Complexities associated with fully integrating global businesses, such as Lima, into core IT, compliance, and distribution structures.
• Non-Cash Goodwill Impairment Exposures: Vulnerability to changes in stock valuation and market capitalization that have historically resulted in significant non-cash impairment charges.
• Indebtedness Covenants & Capital Requirements: Reliance on credit agreements and convertible debt facilities that impose financial leverage restrictions and debt service commitments.
• Global Healthcare Regulations: Stringent compliance standards administered by the FDA and international regulatory authorities, including transitioning product portfolios to the European Union Medical Device Regulation (EU MDR).
• Supply Chain & Cost Inflation: Vulnerabilities to raw material availability, energy pricing, skilled labor tightness, and potential international import tariffs.

Conclusion and Strategic Outlook

Enovis Corporation is positioned as a pure-play medical technology company with an integrated focus on reconstructive surgery and recovery solutions. By leveraging its EGX management system, expanding its surgical product portfolio, and integrating major global acquisitions, the enterprise aims to drive long-term value creation and improved patient motion across global healthcare markets.

Official Site

Official Corporate Website: https://www.enovis.com

Income Statement / Profit and loss

Balance sheet

Cash flow

Subsidiaries & Joint Ventures

• Enovis operates through various global operating subsidiaries and regional distribution networks across North America, Europe, Africa, Asia, and Australia, including LimaCorporate S.p.A. and its global operating entities.

Other Investments & Holdings

• The Company holds investments of $21.4 million in privately held companies without readily determinable fair values, primarily within the Prevention & Recovery segment, including one investment accounted for under the equity method and others accounted for under the cost method.

Physical properties

• Corporate headquarters located in Wilmington, Delaware.
• Prevention & Recovery segment: 5 production, distribution, and warehousing facilities in the U.S. (241,000 square feet of leased space) and 11 facilities outside the U.S. (925,000 square feet of leased space).
• Reconstructive segment: 4 facilities in the U.S. (213,000 square feet of leased space) and 4 facilities outside the U.S. (268,000 square feet of owned space and 18,000 square feet of leased space).

Investments and capital expenditure

• Capital expenditures for purchases of property, plant, equipment, and intangibles were $197.4 million in 2025, $180.7 million in 2024, and $122.2 million in 2023.
• Research and development expenses were $120.3 million in 2025, $91.3 million in 2024, and $75.3 million in 2023.

Shareholding pattern / Ownership

Frequently Asked Questions